Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2025-1846

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Sahar Ansari, Manali Kamdar, Eniko Papp, Mazyar Shadman, Jeremy Abramson, Begüm D. Topçuoglu, Pei Yang, Lara Stepan, Pradipta Ray, Amanda Przespolewski, Krishna R. Juluri, Eric Bleickardt, Debasmita Roy, Alessandro Crotta, Timothy B. Campbell, Julie A. Rytlewski, Abood Okal, Ethan Thompson, Leanne Peiser

Blood (2025) 146 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2025-1775

Published: 2025

Journal Articles

Optimizing the treatment of secondary central nervous system lymphoma (SCNSL) with intensive systemic and cns-targeted chemoimmunotherapy followed by autologous stem cell transplant (ASCT): A retrospective, single-center analysis of a modified ferreri protocol

Fnu Amritpal Singh, Ajay Major, Cassandra Duarte, Jagar Jasem, Manali Kamdar, Douglas Ney, Bradley Haverkos, Steven Bair

Blood (2025) 146 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2025-2727

Published: 2025

Journal Articles

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Karan Chohan, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

Blood (2025) 146 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2025-5520

Published: 2025

Journal Articles

MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)

Blood (2025) 146 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2025-5944

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

XI Yang, Henry Dumke, Joseph Schroers-Martin, Yazeed Sawalha, Sree Lanka, Izel Okcu, Grzegorz Nowakowski, Peter Doukas, Reem Karmali, Meryl Colton, Michael Spinner, Vincenzo Pizzuti, Manali Kamdar, Olutobi Adewale, Yun Kyoung Tiger, Kelsey Baron, Allison Bock, Marcus Geer, Yasmin Karimi

Blood (2025) 146 (Supplement 1): 783.

https://doi.org/10.1182/blood-2025-783

Published: 2025

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status

Tycel J. Phillips, Alexey V. Danilov, Jia Ruan, Krish Patel, Anita Kumar, Yucai Wang, Gregory A. Maglinte, Erlene Seymour, Manali Kamdar

Blood (2024) 144 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2024-204269

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Yixie Zhang, Ashley Bonner, Matthew Lunning

Blood (2024) 144 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2024-200937

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Optimizing the treatment of secondary central nervous system lymphoma (SCNSL) with intensive systemic and cns-targeted chemoimmunotherapy followed by autologous stem cell transplant (ASCT): A retrospective, single-center analysis of a modified ferreri protocol

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only